Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

894P - Diffuse large B-cell testicular lymphomas (DLBCL-TL): Survival outcomes over 20 years


17 Sep 2020


E-Poster Display


Tumour Site



Gonçalo Nogueira-Costa


Annals of Oncology (2020) 31 (suppl_4): S590-S598. 10.1016/annonc/annonc261


G. Nogueira-Costa1, M. Céu Trindade2, I. Miguel3, A. Nunes2, M. Gomes da Silva2

Author affiliations

  • 1 Medical Oncology, Hospital Nossa Senhora do Rosário (Centro Hospitalar Barreiro Montijo, EPE), 2834-003 - Barreiro/PT
  • 2 Hematology, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 - Lisboa/PT
  • 3 Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 - Lisboa/PT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 894P


Due to their rarity (1-2% NHL, < 5% testicular neoplasms), treatment recommendations for DLBCL-TL are based on phase II studies. It is an aggressive entity more frequent in the elderly and prone to distant dissemination. After surgical resection, systemic treatment (anthracycline plus rituximab based), contralateral radiotherapy (RT) and central nervous system (CNS) prophylaxis are recommended. We characterized survival outcomes and relapse patterns in a single center over 20 years.


Retrospective analysis of consecutive DLBCL-TL patients (pts) diagnosed and treated in a tertiary cancer center between 2000-2020. Demographic and clinical variables were retrieved from pts charts. Overall (OS) and progression free survival (PFS) were determined by Kaplan Meier method and stratified according to IPI.


Thirty pts (4% of all DLBCL), median age 68.5 y (42-87), ECOG PS ≤2 were analyzed. Bilateral involvement was diagnosed in 10.0% and advanced disease (IIIE-IV) in 40.0%. Elevated LDH was found in 40.0% and 26.6% had >1EN site. Eleven pts were IPI low risk (L), 6 low-intermediate (L-I) and 13 intermediate-high and high (I-H+H). 19/24 pts had non-GC tumors by Hans algorithm. RCHOP like regimens were applied to 93.3% pts. Testicular RT was offered to 19 pts and CNS prophylaxis to 27 pts (27/27 intrathecal and 16/27 additional systemic methotrexate). With a median follow up of 46 mo, 16 pts progressed and 13 died. Median PFS and OS was 22.6 and 31.9 mo. One third of relapses affected EN sites; 45% occurred >2 years. OS in the L, L-I and I-H+H risk groups were 100%, 83.3% and 61.5% at 2y and 81.8%, 83.3% and 38.5% at 5y respectively. Corresponding values for PFS were 100%, 83.3% and 46.2% at 2y and 81.8%, 83.3% and 23.1% at 5 y. For comparison, OS of non-testicular DLBCL pts at 5y varied between 87.2% in L and 49.8% in H risk groups. Estimated median OS was not reached (NR) in the L and L-I and was 39.7mo (95% CI: 1.2-78.1) in the I-H+H risk groups (p=0.02).


We confirm the prognostic impact of IPI in DLBCL-TL as high risk pts have limited survival outcomes, emphasizing the importance of early diagnosis and the need for new, tolerable therapeutic strategies in the elderly. TL presents a continuous pattern of relapse requiring prolonged follow up.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.